Oppenheimer raised the firm’s price target on Praxis Precision (PRAX) to $250 from $115 and keeps an Outperform rating on the shares. The firm says the company surprised investors with a “double-win” in the Phase 3 ESSENTIAL3 program for ulixacaltamide in essential tremor. Ulixacaltamide met all endpoints in Study-1 and its primary endpoint in Study-2 with a competitive safety profile compared to incumbent propranolol, the analyst tells investors in a research note. The firm says Study-1’s “unexpected success” provides a clear regulatory path forward for ulixacaltamide. Opco sees a potential FDA approval in 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Praxis Precision price target raised to $251 from $61 at TD Cowen
- Praxis Precision price target raised to $360 from $85 at Truist
- Optimistic Buy Rating for Praxis Precision Medicines Amid Positive Phase 3 Results and Strategic Advancements
- Praxis Precision price target raised to $275 from $76 at Baird